Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Shares Outstanding (Weighted Average) (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Shares Outstanding (Weighted Average) readings, the most recent being $9.9 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 57.79% to $9.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.9 million, a 57.79% increase, with the full-year FY2025 number at $9.9 million, up 57.79% from a year prior.
  • Shares Outstanding (Weighted Average) hit $9.9 million in Q4 2025 for Aligos Therapeutics, up from $9.7 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $156.4 million in Q2 2024 to a low of $1.7 million in Q3 2023.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $38.4 million (2021), compared with a mean of $38.9 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 299.03% in 2021 and later crashed 95.93% in 2023.
  • Aligos Therapeutics' Shares Outstanding (Weighted Average) stood at $39.9 million in 2021, then increased by 7.13% to $42.7 million in 2022, then plummeted by 94.0% to $2.6 million in 2023, then surged by 144.38% to $6.3 million in 2024, then surged by 57.79% to $9.9 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $9.9 million (Q4 2025), $9.7 million (Q3 2025), and $9.4 million (Q2 2025) per Business Quant data.